ATTO Stock Chart & Stats
$25.55
--
Market closed
$25.55
--
Day’s Range― - ―
52-Week Range$16.15 - $28.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)427.96K
Market Cap
$1.03B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.60
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.4%
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,651,260
10 Day Avg. Volume169,227
30 Day Avg. Volume427,957
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$39.75Price Target Upside55.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Attovia Therapeutics, Inc. News
ATTO FAQ
What was Attovia Therapeutics, Inc.’s price range in the past 12 months?
Attovia Therapeutics, Inc. lowest stock price was $16.15 and its highest was $28.00 in the past 12 months.
What is Attovia Therapeutics, Inc.’s market cap?
Attovia Therapeutics, Inc.’s market cap is $1.03B.
When is Attovia Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Attovia Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Attovia Therapeutics, Inc. overvalued?
According to Wall Street analysts Attovia Therapeutics, Inc.’s price is currently Undervalued.
Does Attovia Therapeutics, Inc. pay dividends?
Attovia Therapeutics, Inc. pays a Notavailable dividend of $1.709 which represents an annual dividend yield of 3.4%. See more information on Attovia Therapeutics, Inc. dividends here
What is Attovia Therapeutics, Inc.’s EPS estimate?
Attovia Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Attovia Therapeutics, Inc. have?
Attovia Therapeutics, Inc. has 45,651,260 shares outstanding.
What happened to Attovia Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Attovia Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ATTO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Attovia Therapeutics, Inc. Stock Smart Score
Company Description
Attovia Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
ATTO Stock 12 Month Forecast
Average Price Target
$39.75
▲(55.58% Upside)